Attovia Therapeutics, Inc.: Alamar HoldCo, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Alamar HoldCo, LLC disclosed a stake exceeding 5% in Attovia Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0002148983-26-000005). The passive-investment disclosure signals a significant new institutional holder in the biotech. Specific share counts and ownership percentage were not detailed in the filing headline. Investors will watch for further 13G/13D amendments and any changes in Alamar's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Attovia Therapeutics, Inc., Alamar HoldCo, LLC